228 related articles for article (PubMed ID: 25936304)
1. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden.
Dittrich-Riediger J; Schatz U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():45-52. PubMed ID: 25936304
[TBL] [Abstract][Full Text] [Related]
2. Actual situation of lipoprotein apheresis in Saxony in 2013.
Emmrich U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
[TBL] [Abstract][Full Text] [Related]
3. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
Groß E; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
5. The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience.
Sampietro T; Sbrana F; Bigazzi F; Ripoli A; Dal Pino B; Pasanisi EM; Petersen C; Coceani M; Luciani R; Pianelli M
Atheroscler Suppl; 2015 May; 18():268-72. PubMed ID: 25936336
[TBL] [Abstract][Full Text] [Related]
6. Factors inducing cardiovascular events in patients treated by lipoprotein apheresis.
Taseva K; Fischer S; Passauer J; Weiss N; Bornstein SR; Julius U
Atheroscler Suppl; 2013 Jan; 14(1):45-50. PubMed ID: 23357140
[TBL] [Abstract][Full Text] [Related]
7. Current situation of lipoprotein apheresis in Saxony.
Julius U; Taseva K; Fischer S; Passauer J; Bornstein SR
Atheroscler Suppl; 2013 Jan; 14(1):51-5. PubMed ID: 23357141
[TBL] [Abstract][Full Text] [Related]
8. Effects of different lipoprotein apheresis methods on serum protein levels.
Julius U; Siegert G; Kostka H; Schatz U; Hohenstein B
Atheroscler Suppl; 2015 May; 18():95-102. PubMed ID: 25936311
[TBL] [Abstract][Full Text] [Related]
9. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H; Vogt A;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
[TBL] [Abstract][Full Text] [Related]
10. Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany's largest apheresis center).
Heigl F; Hettich R; Lotz N; Reeg H; Eder B; Steckholzer-Kroth K; Browatzki M; Harre K; Arendt R
Atheroscler Suppl; 2009 Dec; 10(5):137-41. PubMed ID: 20129393
[TBL] [Abstract][Full Text] [Related]
11. First data from the German Lipoprotein Apheresis Registry (GLAR).
Schettler VJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Ramlow W; Blume H;
Atheroscler Suppl; 2015 May; 18():41-4. PubMed ID: 25936303
[TBL] [Abstract][Full Text] [Related]
12. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
von Dryander M; Fischer S; Passauer J; Müller G; Bornstein SR; Julius U
Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139
[TBL] [Abstract][Full Text] [Related]
13. Mental symptoms and quality of life in lipoprotein apheresis patients in comparison to hemodialysis patients, platelet donors and normal population.
Stasiewski E; Christoph M; Christoph A; Bittner A; Weidner K; Julius U
Atheroscler Suppl; 2015 May; 18():233-40. PubMed ID: 25936331
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein apheresis--more than just cholesterol reduction?
Neumann CL; Schulz EG; Hagenah GC; Platzer U; Wieland E; Schettler V
Atheroscler Suppl; 2013 Jan; 14(1):29-32. PubMed ID: 23357137
[TBL] [Abstract][Full Text] [Related]
15. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
Schampera S; Fischer S; Weiss N; Julius U
Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of long-term lipid apheresis at a single center.
Koziolek MJ; Hennig U; Zapf A; Bramlage C; Grupp C; Armstrong VW; Strutz F; Müller GA
Ther Apher Dial; 2010 Apr; 14(2):143-52. PubMed ID: 20438535
[TBL] [Abstract][Full Text] [Related]
17. The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorption.
Julius U; Tselmin S; Fischer S; Passauer J; Bornstein SR
Atheroscler Suppl; 2009 Dec; 10(5):12-6. PubMed ID: 20129367
[TBL] [Abstract][Full Text] [Related]
18. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
[TBL] [Abstract][Full Text] [Related]
19. One year experience with a low density lipoprotein apheresis system.
Durst R; Rund D; Schurr D; Eliav O; Ben-Yehuda D; Shpizen S; Ben-Avi L; Schaap T; Pelz I; Leitersdorf E
Isr Med Assoc J; 2002 Sep; 4(9):677-80. PubMed ID: 12440228
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]